Apellis Pharmaceuticals Inc Precio/Valor contable
¿Qué es el Precio/Valor contable de Apellis Pharmaceuticals Inc?
El Precio/Valor contable de Apellis Pharmaceuticals Inc es 27.93
¿Cuál es la definición de Precio/Valor contable?
El ratio precio-valor contable representa la relación entre el valor de las acciones de una empresa y el valor contable por acción.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Precio/Valor contable de compañías en Sector Health Care en NASDAQ en comparadas con Apellis Pharmaceuticals Inc
¿Qué hace Apellis Pharmaceuticals Inc?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Empresas con precio/valor contable similar a Apellis Pharmaceuticals Inc
- Eidos Therapeutics Inc tiene Precio/Valor contable de 27.71
- Cauldron tiene Precio/Valor contable de 27.73
- Shakti Pumps (India) tiene Precio/Valor contable de 27.77
- Abbvie Inc tiene Precio/Valor contable de 27.83
- Dixon Technologies (India) tiene Precio/Valor contable de 27.84
- Tata Elxsi tiene Precio/Valor contable de 27.89
- Apellis Pharmaceuticals Inc tiene Precio/Valor contable de 27.93
- Adani Gas tiene Precio/Valor contable de 27.94
- Livongo Health tiene Precio/Valor contable de 27.99
- SAB Events & Governance Now Media Private tiene Precio/Valor contable de 28.10
- Colonial Coal International tiene Precio/Valor contable de 28.14
- BikeExchange Pty Ltd tiene Precio/Valor contable de 28.19
- Confidence Intelligence tiene Precio/Valor contable de 28.20